New Discoveries in Alzheimer's and Dementia Research Highlighted at 2025 Alzheimer's Association International Conference

New discoveries in Alzheimer's and Dementia Research Highlighted at 2025 Alzheimer's Association International Conference

New research results reported at the Alzheimer’s Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer’s disease and other dementias.  This year’s conference in Toronto attracted nearly 19,000 registered attendees and included more than 6,400 scientific submissions.  “AAIC is a cornerstone event for Alzheimer’s researchers—and for everyone committed to a future without …

Early Alzheimer's patients continue to benefit from 4 yrs of LEQEMBI(R) (lecanemab-irmb) Therapy, new clinical data presented at AAIC - Express Pharma

Eisai Co announced that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer’s Association International Conference (AAIC) 2025, held in Toronto, Canada, and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofib…

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

TOKYO and CAMBRIDGE, Mass., July 30, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the two-year real-world study in…